AGL 38.50 Decreased By ▼ -0.06 (-0.16%)
AIRLINK 211.70 Increased By ▲ 3.93 (1.89%)
BOP 9.98 Decreased By ▼ -0.08 (-0.8%)
CNERGY 6.60 Decreased By ▼ -0.48 (-6.78%)
DCL 9.58 Decreased By ▼ -0.41 (-4.1%)
DFML 39.90 Decreased By ▼ -1.24 (-3.01%)
DGKC 99.20 Decreased By ▼ -4.26 (-4.12%)
FCCL 34.99 Decreased By ▼ -1.36 (-3.74%)
FFBL 87.90 Decreased By ▼ -3.69 (-4.03%)
FFL 13.98 Decreased By ▼ -0.62 (-4.25%)
HUBC 133.50 Decreased By ▼ -5.93 (-4.25%)
HUMNL 14.00 Decreased By ▼ -0.10 (-0.71%)
KEL 5.65 Decreased By ▼ -0.32 (-5.36%)
KOSM 7.34 Decreased By ▼ -0.52 (-6.62%)
MLCF 46.00 Decreased By ▼ -1.28 (-2.71%)
NBP 66.38 Decreased By ▼ -7.38 (-10.01%)
OGDC 219.99 Decreased By ▼ -2.67 (-1.2%)
PAEL 38.49 Increased By ▲ 0.38 (1%)
PIBTL 8.84 Decreased By ▼ -0.43 (-4.64%)
PPL 199.90 Decreased By ▼ -5.95 (-2.89%)
PRL 40.30 Increased By ▲ 0.45 (1.13%)
PTC 25.90 Decreased By ▼ -0.72 (-2.7%)
SEARL 102.99 Decreased By ▼ -7.25 (-6.58%)
TELE 9.10 Decreased By ▼ -0.13 (-1.41%)
TOMCL 37.25 Decreased By ▼ -0.96 (-2.51%)
TPLP 13.90 Increased By ▲ 0.13 (0.94%)
TREET 25.48 Decreased By ▼ -0.97 (-3.67%)
TRG 58.50 Decreased By ▼ -2.04 (-3.37%)
UNITY 33.60 Decreased By ▼ -0.54 (-1.58%)
WTL 1.73 Decreased By ▼ -0.15 (-7.98%)
BR100 11,977 Decreased By -321.6 (-2.61%)
BR30 37,542 Decreased By -1335.8 (-3.44%)
KSE100 111,724 Decreased By -3136.6 (-2.73%)
KSE30 35,076 Decreased By -1119.9 (-3.09%)

LONDON: The European Commission has contracted Pfizer and several European companies to reserve capacity to make up to 325 million vaccines per year in case of a future global health emergency, it said on Friday.

The agreement, first reported by Reuters earlier in the day, covers mRNA, vector-based and protein-based vaccines and does not relate to existing COVID-19 vaccine agreements between the EU and vaccine makers including Pfizer.

The European Commission said in a statement announcing the deal that the COVID pandemic showed that Europe needs to be better prepared for future health emergencies.

The deal ensures that companies are ready “to respond to a crisis” by keeping their facilities up to date and monitoring their supply chains, “including stockpiling where necessary”, the Commission said. If a new public health emergency is declared, companies would “rapidly start production”, it said.

US FDA approves Pfizer’s COVID antiviral pill

But vaccine equity activists said the EU risked a repeat of what the World Health Organization dubbed “vaccine apartheid” during COVID-19.

“After a pandemic in which developing countries were sent to the back of the queue for vaccines and treatments, the EU and pharmaceutical companies seem to be planning to do it all over again in the next health crisis,” said Mohga Kamal-Yanni, policy co-lead for the People’s Vaccine Alliance.

The Commission has selected Pfizer’s plants in Ireland and Belgium to reserve capacity to produce mRNA vaccines. It selected Spanish companies Reig Jofre and Laboratorios Hipra SA to reserve capacity for protein-based vaccines and Bilthoven Biologicals B.V. of the Netherlands for vector-based vaccines. None of the companies immediately responded to a request for comment.

Pfizer leans on Covid products to top estimates

The World Health Organisation has urged governments and manufacturers to reserve up to 20% of any tests, vaccines or treatments for the global agency to distribute in poorer countries to avoid a repeat of the “catastrophic failure” during the COVID pandemic, according to a draft of a global pandemic agreement currently being discussed.

Comments

Comments are closed.